Discovery of an l-alanine ester prodrug of the Hsp90 inhibitor, MPC-3100

Add time:08/30/2019    Source:sciencedirect.com

Various types of Hsp90 inhibitors have been and continue to undergo clinical investigation. One development candidate is the purine-based, synthetic Hsp90 inhibitor 1 (MPC-3100), which successfully completed a phase I clinical study. However, further clinical development of 1 was hindered by poor solubility and consequent formulation issues and promoted development of a more water soluble prodrug. Towards this end, numerous pro-moieties were explored in vitro and in vivo. These studies resulted in identification of l-alanine ester mesylate, 2i (MPC-0767), which exhibited improved aqueous solubility, adequate chemical stability, and rapid bioconversion without the need for solubilizing excipients. Based on improved physical characteristics and favorable PK and PD profiles, 2i mesylate was selected for further development. A convergent, scalable, chromatography-free synthesis for 2i mesylate was developed to support further clinical evaluation.

We also recommend Trading Suppliers and Manufacturers of L-ALANINE METHYL ESTER (cas 114041-77-9). Pls Click Website Link as below: cas 114041-77-9 suppliers

Prev:Polymer paperThermo-response of ion track pores in copolymer films of methacryloyl-L-ALANINE METHYL ESTER (cas 114041-77-9) and diethyleneglycol-bis-allylcarbonate
Next:Preparation of l-alanine ethyl ester modified multiwalled carbon nanotubes and their chiral discrimination between d- and l-tryptophan)